Evaluating the preclinical efficacy and safety of the ANCD in a swine clot model
Abstract
Background The Advanced Thrombectomy System (ANCD) provides a new funnel component designed to reduce clot fragmentation an...
Anaconda Biomed S.L. Secures €20 Million Round of Funding
(PICTURE: from left to right) Sylvain Sachot, Investment Director at ASABYS Partners; François Salmon, CEO of Anaconda Biomed S.L, Jose...
Anaconda Biomed Announces First-in-Human Study of Next-Generation Thrombectomy System
Anaconda Biomed, a medical technology company developing a next-generation thrombectomy system for the treatment of ischemic s...
NEW GRANT: NUCLIS ACCIÓ – GENERALITAT DE CATALUNYA
ANACONDA BIOMED gets a grant from ACCIÓ, the Agency for Business Competitiviness of la Generalitat de Catalunya. With this new s...
Cristophe Cognard, PhD. joins Anaconda Biomed as latest member of the SAB
Prof. Christophe Cognard is the Chairman of the Department of Diagnostic and Therapeutic Neuroradiology, University Hospitals Purpan an...
ANCD thrombectomy device: in vitro evaluation
Endovascular treatment of stroke, although highly effective, may fail to reach complete recanalization in around 20% of cases....
PREMI REVOLUCIÓ 4.0: Salut Tecnológica 2019
Last April, Anaconda Biomed S.L. was awarded the "Health Technological" award of the Revolució 4.0. The leading entrepreneurship and in...
Anaconda Biomed S.L. Expands Leadership Team with Two New Senior Hires
Anaconda Biomed S.L has announced the appointment of two new senior executives. Lieven Huysse, M.D., has joined the company as chief me...
Preliminary In Vitro Data on Anaconda Biomed’s S.L. Advanced Thrombectomy System Presented at ABC WIN 2019
Anaconda Biomed's S.L. Advanced Thrombectomy System for ischemic stroke outperforms competition in preliminary in vitro data presented ...